Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $5,457,268.11 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares in the company, valued at approximately $6,131,472.24. The trade was a 47.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Eliyahu Sharon Kalif also recently made the following trade(s):

• On Thursday, February 26th, Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $34.08 on Tuesday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The firm has a market capitalization of $39.18 billion, a price-to-earnings ratio of 25.62, a price-to-earnings-growth ratio of 3.32 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35. The company has a 50 day moving average price of $31.59 and a 200 day moving average price of $30.60.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

Analysts Set New Price Targets

TEVA has been the subject of several research analyst reports. Truist Financial upped their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Scotiabank boosted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, The Goldman Sachs Group lifted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth grew its position in Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after acquiring an additional 1,739 shares in the last quarter. Franklin Resources Inc. acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $255,000. Flow Traders U.S. LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $238,000. Finally, Cerity Partners LLC lifted its position in shares of Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after purchasing an additional 1,291 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.